Camila Martins dos Santos
Research Subjects
Camila Martins dos Santos has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Martins dos Santos
Tuberculosis Scientific League, Rio de Janeiro, Brazil
1 shared publication - Anete Trajman
Federal University of Rio de Janeiro
1 shared publication - Anna Vassall
London School of Hygiene and Tropical Medicine, London, UK
1 shared publication - Frank G. Cobelens
Department of Global Health, Academic Medical Center, Amsterdam Institute for Global Health and Development, University of Amsterdam, Amsterdam, the Netherlands.
1 shared publication - Gabriela B. Gomez
Amsterdam Institute for Global Health and Development and Department of Global Health, Academic Medical Center, University of Amsterdam, Trinity Building C, Pietersbergweg 17, Amsterdam, 1105 BM, The Netherlands.
1 shared publication - Janaína Calaça
Tuberculosis Scientific League, Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 December 2015
- Published by Springer Nature in BMC Health Services Research
- Vol. 16 (1) , 27
Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services
Shortened treatment regimens for tuberculosis are under development to improve treatment outcomes and reduce costs. We estimated potential savings from a societal perspective in Brazil following the introduction of a hypothetical four-month regimen for tuberculosis treatment. Data were gathered in ten randomly selected health facilities in Rio de Janeiro. Health service costs were estimated using an ingredient approach. Patient costs were estimated from a questionnaire administered to 126 patients. Costs per visits and per case treated were analysed according to the type of therapy: self-administered treatment (SAT), community- and facility-directly observed treatment (community-DOT, facility-DOT). During the last 2 months of treatment, the largest savings could be expected for community-DOT; on average USD 17,351-18,203 and USD 43,660-45,856 (bottom-up and top-down estimates) per clinic. Savings to patients could also be expected as the median (interquartile range) patient-related costs during the two last months were USD 108 (13–291), USD 93 (36–239) and USD 11 (7–126), respectively for SAT, facility-DOT and community-DOT. Introducing a four-month regimen may result in significant cost savings for both the health service and patients, especially the poorest. In particular, a community-DOT strategy, including treatment at home, could maximise health services savings while limiting patient costs. Our cost estimates are likely to be conservative because a 4-month regimen could hypothetically increase the proportion of patients cured by reducing the number of patients defaulting and we did not include the possible cost benefits from the subsequent prevention of costs due to downstream transmission averted and rapid clinical improvement with less side effects in the last two months.
- 1 December 2015
- Published by Springer Nature in BMC Health Services Research
- Vol. 16 (1) , 27
Open AccessShortened first-line TB treatment in Brazil: potential cost savings for patients and health services
Shortened treatment regimens for tuberculosis are under development to improve treatment outcomes and reduce costs. We estimated potential savings from a societal perspective in Brazil following the introduction of a hypothetical four-month regimen for tuberculosis treatment. Data were gathered in ten randomly selected health facilities in Rio de Janeiro. Health service costs were estimated using an ingredient approach. Patient costs were estimated from a questionnaire administered to 126 patients. Costs per visits and per case treated were analysed according to the type of therapy: self-administered treatment (SAT), community- and facility-directly observed treatment (community-DOT, facility-DOT). During the last 2 months of treatment, the largest savings could be expected for community-DOT; on average USD 17,351-18,203 and USD 43,660-45,856 (bottom-up and top-down estimates) per clinic. Savings to patients could also be expected as the median (interquartile range) patient-related costs during the two last months were USD 108 (13–291), USD 93 (36–239) and USD 11 (7–126), respectively for SAT, facility-DOT and community-DOT. Introducing a four-month regimen may result in significant cost savings for both the health service and patients, especially the poorest. In particular, a community-DOT strategy, including treatment at home, could maximise health services savings while limiting patient costs. Our cost estimates are likely to be conservative because a 4-month regimen could hypothetically increase the proportion of patients cured by reducing the number of patients defaulting and we did not include the possible cost benefits from the subsequent prevention of costs due to downstream transmission averted and rapid clinical improvement with less side effects in the last two months.